Benzinga | Aug 3, 2021 10:55AM EDT

Canaccord Genuity Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $150

Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy and raises the price target from $101 to $150.